bluebird bio Reports Fiscal Third Quarter 2013 Financial Results
11/15/2013 10:04:32 AM
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2013.
Revenues were $6.4 million during the quarter ended September 30, 2013 compared to $0.1 million for the quarter ended September 30, 2012 and include amounts allocated to research and development services from the Celgene collaboration.
Help employers find you! Check out all the jobs and post your resume.
comments powered by